No Data
Emerging Markets Stock Digest: Daiomu significantly declines, Chordia rebounds significantly after 3 days.
<2160> GNI 2953 +145 sharply extended. They are disclosing questions and answers from investors. On the 14th, the consolidated subsidiary Cullgen entered into a contract for a reverse merger with Pulmatrix, listed on the Nasdaq, and expected to record other income of approximately 14.7 billion 64 million yen (with a stock valuation gain of approximately 10.7 billion 68 million yen), but following an increase in Pulmatrix's stock price, in this disclosure, it was mentioned that "the stock valuation gain we record is also significantly increased".
Active and newly established stocks in the afternoon session.
* Advantest <6857> 8506 -328 fell below the 25-day moving average the previous day, also leading to sell-offs. * Monster Lab <5255> 117 -2 became temporarily popular due to participating in the development of KDDI's retail AI promotional technology solution, but the buying did not continue. * Pixel CZ <2743> 79 +16 signed a sales contract for GPU servers equipped with NVIDIA's H100. * GNI <2160> 2953 +145 the stock price of the consolidated subsidiary involved in the reverse merger has increased.
Chordia Therapeutics---Presentation of research results related to CDK12 inhibitors at the Japan Molecular Biology Society Mini Symposium.
Chordia Therapeutics <190A> announced that it will present research results related to its CDK12 inhibitor pipeline at the 47th Annual Meeting of the Molecular Biology Society of Japan, which will be held on the 26th at Marine Messe Fukuoka, during a mini-symposium and poster session. The company is a research and development-oriented biotech venture specializing in oncology, with clinical development products including the CLK inhibitor rogocekib, the CDK12 inhibitor CTX-439, and the GCN2 inhibitor.
Chordia --- rebounded significantly after three days, with research results on CDK12 inhibitors to be presented at the Japan Society of Molecular Biology.
Marked rebound after 3 days. It has been revealed that the company will present research results related to its CDK12 inhibitor at the Mini Symposium and Poster Sessions of the 47th Japan Society for Molecular Biology to be held on November 27-29. The announcement includes reports on the CDK12 inhibitor targeting RNA control stress through new "RNA trucking" in addition to the known "transcription", and how RNA trucking may impact the extent of the anti-cancer effects of CDK12 inhibitors.
Volume change rate ranking (10 o'clock) - V-Cube, DyDo, etc. are ranked.
In the ranking of volume change rates, by comparing the average volume over the last five days with the volume on the delivery day, one can understand the trends in selection and the interests of market participants. ■ Top volume change rates [As of November 27, 10:32] (Comparing the average volume over the last five days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <3681> V-Cube 3015000345 10.86324.75% 0.0263% <2590>
Chordia Therapeutics - The international nonproprietary name of the pharmaceutical CTX-712 has been established.
Chordia Therapeutics ＜ 190A ＞ announced on the 20th that the World Health Organization (WHO) has publicly released the International Nonproprietary Name (INN) for the CLK inhibitor drug CTX-712, which the company is developing, as the recommended INN (rINN). In the future, this development product will be referred to as "rogocekib" instead of the development code CTX-712. INN is the universal name for pharmaceuticals worldwide.
No Data
No Data